Hanmi Pharmaceutical said on the 13th that it was included in the Dow Jones Sustainability Indices for the second straight year. It was added to the Dow Jones Best-in-Class Korea Index, which is composed based on S&P Global's ESG (environment, social, and governance) assessment.
Hanmi Pharmaceutical was recognized for its efforts toward carbon neutrality and responding to climate change. The company is implementing a no-patent-filing policy in low-income countries. It allows unrestricted production of generics in those countries and is improving access to medicines.
Hanmi Pharmaceutical has built a safety and health management system focused on prevention. Each business sites conducts regular safety inspections twice a year. It identifies and improves risk factors that could cause accidents on its own.
Chief Executive Hwang Sang-yeon of Hanmi Pharmaceutical said, "We will fulfill corporations' social responsibility through ESG management that meets global standards."